Patent expiry and biosimilars: difference between revisions
Diff·revision 9 → 10·11:28, 30 Mar 2025
Difference between revision 9 and revision 10 of Patent expiry and biosimilars. 1 line changed; the page grew by 38 bytes.
| Revision 9 — 02:59, 17 Mar 2025 API_Aurora (talk) add the good-manufacturing-practice framework by name 3,173 bytes ±0 | Revision 10 — 11:28, 30 Mar 2025 BiliaryBea (talk) add the effective date to the regulatory table 3,211 bytes +38 | ||
|---|---|---|---|
| 1 | {{Infobox concept | 1 | {{Infobox concept |
| 2 | | name = Patent expiry and biosimilars | 2 | | name = Patent expiry and biosimilars |
| + | 3 | | subtitle = Intellectual property | |
| 3 | | Generic = Demonstrated identical active substance | 4 | | Generic = Demonstrated identical active substance |
| 4 | | Biosimilar = Highly similar, with comparability exercise | 5 | | Biosimilar = Highly similar, with comparability exercise |